Title: Therapeutic efficacy of prednisone and cyclophosphamide in patients with systemic sclerosis associated interstitial lung disease
Abstract: Objective To investigate the therapeutic efficacy of interstitial lung disease(ILD) in patients with systemic sclerosis(SSc-ILD).Methods Twenty initial treatment patients of SSc-ILD were enrolled.They were divided into A group(early metaphase process,n=12),and B group(advanced stage process,n=8) based on high-resolution computed tomography(HRCT) of chest.The following parameters of two groups were noted at baseline and 24 weeks after treatment with prednisone and Cyclophosphamide(CTX): clinical features,pulmonary function tests,HRCT,quality of life.Results Pulmonary infection happened in 10 patients and the incidence rate was 50%.Hemoglobin,erythrocyte sedimentation rate(ESR) in A group and platelet,ESR,C-reactive protein in B group were significantly improved.HRCT showed that 7(58.3%) patients improved,and 2 had deteriorated disease in A group and 2(25%) patients improved,and 6 had deteriorated disease in B group.HRCT score of A group was decreased,but did not show significant change in B group.Pulmonary function in A group was improved compared with B group(all P0.05).Activity scores,impact scores and total scores of SGRQ were decreased,especially activity scores in B group.SF-36 showed improvement in role-physical(RP),bodily pain(BP),role-emotional(RE),mental health of A group and in physical functioning,RP,BP,RE of B group.Conclusions After treatment with prednisone and CTX,patients of SSc-ILD is inclined to pulmonary infection,and their systemic inflammation,quality of life and exercise capacity can be improved.Pulmonary affection and pulmonary function in most of early metaphase patients can be improved,but has no amendment in advanced stage patients.
Publication Year: 2012
Publication Date: 2012-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot